奈达铂与紫杉醇联合用于转移性食管癌患者的II期评估
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
作者信息
Gong Youling, Ren Li, Zhou Lin, Zhu Jiang, Huang Meijuan, Zhou Xiaojuan, Wang Jin, Lu You, Hou Mei, Wei Yuquan
机构信息
Department of Thoracic Oncology, Tumor Center, West China Hospital, Sichuan University, 610041, Chengdu, People's Republic of China.
出版信息
Cancer Chemother Pharmacol. 2009 Jul;64(2):327-33. doi: 10.1007/s00280-008-0874-8. Epub 2008 Dec 2.
PURPOSE
To evaluate the efficiency and toxicities of nedaplatin and paclitaxel in patients with metastatic carcinoma of the esophagus.
METHODS
Thirty-nine untreated patients with confirmed metastatic tumors were enrolled. Patients were treated with nedaplatin 80 mg/m(2) and paclitaxel 175 mg/m(2) on day 1. Treatment was repeated every 21 days.
RESULTS
Thirty-six patients were eligible to be evaluated to have had a response. The overall response rate was 43.6% (17/39), with complete response and partial response rates of 2.6 and 41%, respectively. The median progression-free survival and overall survival time was 6.1 and 10.3 months, respectively. Grade 3/4 toxicities were only observed in six patients [neutropenia in three patients (7.7%) and nausea/vomiting in three patients (7.7%)].
CONCLUSION
Comparing to other regimens, combination of nedaplatin and paclitaxel achieved an encouraging clinical outcome, with relatively minimal toxicities for patients with metastatic esophageal carcinoma.
目的
评估奈达铂和紫杉醇联合治疗转移性食管癌患者的疗效和毒性。
方法
纳入39例未经治疗的确诊转移性肿瘤患者。患者于第1天接受奈达铂80mg/m²和紫杉醇175mg/m²治疗。每21天重复治疗。
结果
36例患者符合疗效评估标准。总缓解率为43.6%（17/39），完全缓解率和部分缓解率分别为2.6%和41%。无进展生存期和总生存期的中位数分别为6.1个月和10.3个月。仅6例患者出现3/4级毒性反应[3例患者出现中性粒细胞减少（7.7%），3例患者出现恶心/呕吐（7.7%）]。
结论
与其他方案相比，奈达铂和紫杉醇联合治疗转移性食管癌患者取得了令人鼓舞的临床疗效，且毒性相对较小。
Zotero 插件